Recent Development of Antitumor Agents from Chinese Herbal Medicines. Part II. High Molecular Compounds

Abstract

High molecular compounds from Chinese herbal medicines, including ribosome-inactivating proteins and polysaccharides from both fungi and high plants have been tested for the treatment of malignant diseases. Polysaccharides possessing immunostimulating activities can be used as adjuvants in tumor treatment. The fungi containing such polysaccharides are usually edible mushrooms or tonics in Traditional Chinese Medicine. Parts from high plants such as Radix Astragali and Fructus Lycii containing polysaccharides are mainly used as tonic in Traditional Chinese Medicine. Ribosome-inactivating proteins are a group of proteins exerting cytotoxic activities via inhibition of protein synthesis. Some of the ribosome-inactivating proteins have been used as the cytotoxic part in conjugates with monoclonal antibodies as tumor-targeting drugs. The cytotoxic and antineoplastic mechanisms of the high molecular compounds are rather different from those of the low molecular compounds described in part I.

Dedication

In memory of Prof. Dr. Hans Beyer, Prof. Dr. Roland Pohlodek-Fabi and Prof. Dr. Werner Rothmaler, Ernst-Moritz-Arndt University, Greifswald, Germany

Key words

Antitumor agents · Chinese herbal medicines · high molecular natural compounds

Introduction

Besides the low molecular compounds from Chinese herbal medicines as antineoplastic and cytotoxic agents (see “Recent Development of Antitumor Agents from Chinese Herbal Medicines” Part I, Planta Medica 2003; 69: 97 – 108), some high molecular compounds were isolated from Chinese herbal medicines and were used for the treatment of malignant diseases. Among the high molecular compounds, polysaccharides and ribosome-inactivating proteins are of special interest. Polysaccharides from fungi and higher plants exhibiting immunostimulating effects were tested both in experimental and clinical studies. Ribosome-inactivating proteins are a group of proteins which are able to inactivate eukaryotic protein synthesis by attacking the 28S ribosomal RNA. They have been tested experimentally and clinically in the treatment of tumors both as single compounds and as conjugates bound to antibodies. In the present part, a summary of the recent advances in the study and use of polysaccharides and ribosome-inactivating proteins from Chinese herbal medicines for the treatment of tumors is given.

Polysaccharides

Fungal polysaccharides

A number of polysaccharides from fungi were reported to possess immunostimulating and antitumor effects [1], [2]. Lentinan

Affiliation

1 Division of Food Chemistry and Environmental Toxicology, Department of Chemistry, University of Kaiserslautern, Germany
2 Division of Toxicology and Cancer Risk Factors, Deutsches Krebsforschungszentrum, Heidelberg, Germany

Correspondence

Dr. Barbara Bertram · Div. Toxicology and Cancer Risk Factors · Deutsches Krebsforschungszentrum · D-69120 Heidelberg · Phone: +49 (0)6221 423030 · Fax: +49 (0)6221 423031 · E-mail: b.bertram@dkfz.de

Received May 27, 2002 · Accepted December 22, 2002

Bibliography

Planta Med 2003; 69: 193–201 · © Georg Thieme Verlag Stuttgart · New York · ISSN 0032-0943

from *Lentinus edodes* (Berk.) Sing. (Tricholomataceae) is one of the most thoroughly studied fungal polysaccharides. *Lentinus edodes* is a common edible mushroom in China and in Japan. Lentinan was first isolated by Chihara [3]. It is a (1→3)-β-glucan highly branched with (1→3)-β- and (1→6)-β-linked glucose residues existing mainly as linear triple-helical structures in aqueous solution. Lentinan has a molecular weight of about 500 kDa [4, 5].

A multi-center prospective study of lentitan used in combination with cytostatic agents in patients with advanced unresectable and recurrent gastric cancer revealed survival prolongation and improvement in life quality. Median survival time of patients treated with lentitan was significantly longer than that of patients without lentitan treatment (297 days vs. 199 days) [6].

Lentitan at a daily i.v. dosage of 2 mg per patient combined with 5'-deoxy-5-fluorouridine [7], cisplatin, 5-FU [8] and tegafur [9] was effectively used for postoperative therapy of gastric cancer. An increase of more than 50% IL-1β production in the peripheral blood of gastric cancer patients associated with lentitan treatment was observed [10], [11] as well as an enhanced induction of lymphokine-activated NK cell activity [12]. Addition of lentitan to maintenance therapy with 5-FU did not exert prognostic benefit on hepatocellular carcinoma patients [13].

Lentitan exhibited significant immunostimulating effects and showed antitumor activities also in experimental animals, augmenting helper T cell-mediated cytotoxic T cell activity, NK cell activity and humoral immune responses. Moreover, lentitan activated non-specific cytotoxicity of macrophages in vitro [14] and in vivo [15]. The beneficial effects of lentitan on cellular immune function were also observed in cyclophosphamide-treated mice [5]. Among the cytokine genes, the mRNA levels of IL-1α, IL-1β, TNF-α, IFN-γ and macrophage colony-stimulating in mouse peritoneal cells and splenocytes were markedly induced by lentitan [16]. Combinatory use of 5'-deoxy-5-fluorouridine and lentitan against AH66 ascites hepatoma cells in rats resulted in a significant inhibition of tumor growth as compared with 5'-deoxy-5-fluorouridine alone. Lentitan induced pyrimidine nucleoside phosphorylase activity in the tumor and increased the susceptibility of tumor cells to 5'-deoxy-5-fluorouridine [17]. Lentitan decreased glutathione-S-transferase GST-II and GST-III contents in colon 26 adenocarcinoma tissues transplanted into mice and enhanced the susceptibility of tumor to cisplatin [18]. β-(1→3)-Glucans were reported to be more effective on T cells than B cells [19]. It was also suggested that lentitan affects the tumorous vascular system resulting in the induction of hemorrhagic necrosis which is dependent on T cells in the tumor [20], [21]. In addition, the binding of lentitan to human monocytes may initiate the influence of this compound on the immune system and differ between individuals [22].

Intraperitoneal treatment of mice with lentitan at a dose of 10 mg/kg affected the number, plastic-adherence, and endogenous peroxidase activity of peritoneal cells. Lentitan-stimulated peritoneal macrophages exerted cytotoxicity against several murine and human metastatic tumors, including Lewis lung carcinoma and two human melanomas [23]. Peritoneal carcinomatoses induced in BDIX rats by i.p. injections of syngeneic cells from a colon carcinoma cell line, treated with lentitan (five i.p. injections, 2 days apart at a daily dose of 2 mg/kg, starting on day 14 after tumor cell injection) significantly inhibited the growth of carcinomatoses and increased the life span of the animals [24]. Oral administration of *L. edodes* mycelia to mice suppressed postoperative liver metastasis of primary colorectal cancer and increased the survival period, elevating the activities of NK cells and macrophages in the liver and increasing IL-1β levels in liver and spleen [25]. Combined use of lentitan and IL-2 was found to result in synergistic antitumor and antimetastatic effects in mice against spontaneously metastatic 3-methylcholanthrene-induced fibrosarcoma [26].

Lentitan is relatively non-toxic. The LD$_{50}$ values of lentitan in mice (ICR) and rats (CD) are essentially the same regardless of
species and sex and are estimated to be 250–500 mg/kg by i.v. administration and greater than 2500 mg/kg by i.p., s.c., and oral administration. No remarkable toxic signs specific to lentinan were observed after i.p., s.c., and oral treatment whereas cyanosis, convulsion and death were observed in animals administered i.v. with higher dosages of lentinan [27].

Krestin (PSK) [28], a protein-bound β-glucan containing approximately 25% protein; and PSP [29], a polysaccharide peptide, were isolated from CM-101 strain and COV-1 strain, respectively, of Coriolus versicolor (Fr.) Quel. (Polyporaceae). PSP possesses a molecular weight of approximately 100 kDa. Glutamic and aspartic acids are abundant in its polypeptide component, its polysaccharide component is composed of monosaccharides with α-(1→4)- and β-(1→3) glucosidic linkages. The presence of fucose in PSK and rhamnose and arabinose in PSP distinguishes the two protein-bound polysaccharides, which are otherwise chemically similar [1].

In Japanese trials carried out since 1970, krestin significantly extended the five-year survival in cancers of the stomach, colon-rectum, esophagus, nasopharynx, lung (non-small cell), and in a HLA B40-positive breast cancer subset [1]. However, a retrospective study on 963 Japanese patients with gastric cancer of post-operative survival treated with or without PSK showed no significant differences as compared to untreated patients at any stage [30]. PSP, subjected to Phase II and Phase III double-blind trials in China, significantly extended five-year survival time in esophageal cancer. Moreover, it significantly improved life quality, provided substantial pain relief, and enhanced immune status in 70%–97% of patients with cancers of the stomach, esophagus, lung, ovary, and cervix [1].

In experimental studies, krestin was reported to exert a preventive effect on spontaneously developed carcinoogenesis as well as on carcinogen- or radiation-induced tumors [31]. Krestin prolonged the survival time of SD rats bearing mammary tumors induced by N-methyl-N-nitrosourea, when given at a dose of 250 mg/kg twice a week for 3 weeks [32]. Moreover, it inhibited the growth of LLC-WRC-256 (Walker 256 fibrosarcoma) cells, H4-II-E (rat hepatoma) and of H4-II-E-C3 (rat hepatoma) cells in vitro at a concentration of 500 μg/ml [33]. Krestin enhanced the cytotoxicity of cisplatin toward H4-II-E and human ovarian cancer cells [34] and stimulated the production of IL-1 by human peripheral blood mononuclear cells [35]. The combined use of krestin with granulocyte-colony-stimulating factor, granulo-cyte/macrophage-colony-stimulating factor and IL-3 led to an improved recovery of myelosuppression in BDF1 mice induced by an i.v. administration of 5-FU (150 mg/kg) [36].

Obviously, krestin has also antimetastatic effects since it was reported to suppress pulmonary metastasis of methylcholanthrene-induced sarcomas, human prostate cancer DU145M and mouse melanoma cells and lymphatic metastasis of mouse leukemia P388. The survival time of tumor-bearing animals in spontaneous metastasis models was prolonged. Krestin also inhibited metastasis of rat hepatoma AH60C, mouse colon cancer colon 26, and mouse leukemia RL male 1 in artificial metastasis models. The antimetastatic effect of krestin is suggested to depend on different mechanisms: suppressed tumor invasion, adhesion and production of cell matrix-degrading enzymes, suppression of tumor cell attachment to endothelial cells by the inhibition of tumor cell-induced platelet aggregation, suppression of tumor cell migration after extravasation through the inhibition of tumor cell motility, and, finally, suppression of tumor growth after extravasation through the inhibition of angiogenesis, modulation of cytokine production, and augmentation of effector cell functions [37], [38], [39].

In addition, krestin was reported to enhance selenium-dependent and selenium-independent glutathione peroxidase (GST) activity, and to increase selenium-dependent glutathione peroxidase and GST-P mRNA expression in mouse peritoneal macrophages [40]. Krestin also enhanced manganese superoxide dismutase activity and its mRNA expression in mouse peritoneal macrophages [41]. Krestin was further reported to up-regulate inducible nitric oxide synthase (iNOS) gene expression and nitric oxide production in mouse peritoneal polymorpho-nuclear leukocytes. The stimulated production of nitric oxide in combination with IFN-γ may regulate the immune system in vivo [42].

PSP did not show cytotoxicity against tumor cell lines and mouse peritoneal macrophages in vitro at concentrations of 2.5–10 μg/ml. It activated the transcription of TNF gene in these cells, indicating that PSP exerted an immunomodulatory effect on the defensive cells [43]. Both mouse lymphocytes and macrophages were activated by preparations of polysaccharide from cultured mycelia and culture medium of C. versicolor [29]. PSP as a biological response modifier induced the production of IFN-α, IFN-γ, IL-2, and induced T cell proliferation. It counteracted the depressive effect of cyclophosphamide on leukocyte count [44] and showed a restorative effect against spleen injury in mice induced by γ-irradiation [45]. At a daily i.p. dose of 25 mg/kg to mice for 5 days, PSP antagonized the inhibition of IL-2 production by cyclophosphamide from activated T lymphocytes and restored the suppressed T cell-mediated delayed type hypersensitivity response to normal values. The lymphocyte proliferation in vitro was also stimulated by incubation with PSP at concentrations of 100–800 μg/ml. Moreover, PSP increased the phagocytic functions of the host reticulo-endothelial system [46]. PSP given s.c. to BALB/c mice inoculated s.c. with H238 tumor, a murine tumor transformed by herpes virus type 2, at a dose of 2 mg per mouse for 10 days significantly inhibited tumor progression when given immediately after tumor cell injection [47].

A refined polysaccharide peptide fraction from PS was reported to concentration-dependently inhibit the proliferation of the human hepatoma cell line HEPG2, with an IC50 value of 243 μg/ml after an exposure of three days. However, little or no inhibitory effects of the refined polysaccharide peptide were observed on the proliferation of normal human fetal hepatocytes. In tumor-bearing nude mice, 5 days after inoculation with S180 cells, i.v. administration of refined polysaccharide peptide significantly suppressed the growth of S180 cells with an inhibition rate of more than 93% on day 13. Intraperitoneal pretreatment of nude mice with the refined polysaccharide peptide for two weeks before S180 cell inoculation led to a lower incidence of tumor growth than in control mice without polysaccharide pretreatment. The tumor size of the control group was about 3–5 times bigger than that of animals.
with polysaccharide pretreatment. The refined polysaccharide peptide did not cause any pathological lesions in vital organs of rabbits such as heart, liver, spleen, lung and kidney [48].

Further fungal polysaccharides with immunostimulating and antitumor activities have been isolated from Auricularia auricula (L. ex Hook) Underw. (Auriculariaceae) [49], Armillariella tabescens (Scop. ex Fr.) Sing (Tricholomataceae) [50], Ganoderma lucidum Leys. ex Fr.) Karst. (Polyporaceae) [51], Polyporus umbellatus (Pers.) Fries (Polyporaceae) [52], [53], [54], Poria cocos (Schw.) Wolf (Polyporaceae) [55], [56] and Tremella fuciformis Berkely (Tremellaceae) [57], [58], [59]. Ganoderma (Lingzhi); the fruiting body of G. lucidum; Poria (Fuling), the sclerotium of P. cocos; and Polyporus (Zhuling), the fungal body of P. umbellatus, are all listed in the Chinese Pharmacopoeia.

**Polysaccharides from higher plants**

Radix Astragali (Huangqi), the root of Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. (Fabaceae), listed in the Chinese Pharmacopoeia, is used as a general tonic in Traditional Chinese Medicine since ancient time. A series of polysaccharides such as astragalans I–III, AG-I, AG-II, AH-I, AH-II, Amem-P and Amon-S were isolated from the roots of *A. membranaceus* or of *A. membranaceus* var. *mongholicus* [60], [61], [62], [63]. Astragalan I is composed of α-glucose, α-galactose, and α-arabinose in addition to trace amounts of pentose with an average molecular weight of 36.3 kDa. The sugar component in both astragalans II and III is D-glucose. The average molecular weights of astragalans II and III are 12.3 kDa and 34.6 kDa, respectively. Astragalan II and astragalan III consist mainly of α(1→4)-linked glucopyranosyl residues and a small amount of α(1→6)-linked glucopyranosyl residues [61]. AG-I is an α-glucan with α(1→4) and α(1→6) linkages, while AG-2 is an α(1→4)-glucan. The component sugars in AH-1 were identified as galacturonic acid, glucuronic acid, glucose, rhamnose, and arabinose, those in AH-2 as glucose and arabinose [62]. Amon-S is composed of α-arabinose, α-galactose, α-galacturonic acid and α-glucuronic acid, in addition to small amounts of O-acetyl groups and a peptide moiety [63].

An extract of the root of *A. membranaceus* was reported to exert immunostimulating activities in various test systems enhancing the NK activity of lymphocyte effector cells and acting synergistically with partially purified human IFN-α [65]. Another extract of the root was reported to significantly enhance the activity of IL-2, of B cell growth factor and IL-6 in vitro and of phytohemagglutinin-induced proliferation of T lymphocytes from patients with IgG subclass deficiency [66]. The administration of a polysaccharide fraction of *A. membranaceus*, which consists mainly of astragalans I and II, to mice at a daily dose of 1 g/kg i.p. for 6 days stimulated humoral immune functions and restored immunosuppression of mice caused by prednisolone and cyclophosphamide [67], [68]. After i.p. administration, the extract increased weight and cell number of mouse spleen, elevated the response of mouse spleen against sheep red blood cells, and stimulated the phagocytic activity of peritoneal macrophages [69]. Astragalans enhanced the secretion of TNF from human peripheral blood mononuclear cells in vitro [70].

The aqueous extract of the root of *A. membranaceus* was reported to inhibit the DNA synthesis in ovari-an mucinous cystadenoma and ovarian papillary cystadenoma cells in a dose- and time-dependent manner [71]. Ten days following tumor cell transplantation an i.p. treatment with the extract inhibited the growth of murine renal cell carcinoma in BALB/c mice. The cure rate was 57% when the initial tumor load was 2 × 10^5 cells and 100% when the initial tumor load was 1 × 10^6 cells. Splenocytes from mice transplanted with renal carcinoma cells responded less favorably to IL-2 in generating lymphokine-activated killer cells; this depression was restored after treatment with Astragalus extract. It was suggested that *A. membranaceus* may exert its antitumor effect via augmentation of phagocyte and lymphokine-activated NK cell activities [72], [73]. The root of *A. membranaceus* was reported to be used as clinical adjuvant in radiotherapy or chemotherapy of cancer, such as small cell lung cancer [74]. A significant immunoregenerative activity of the polysaccharide fraction with an increased local xenogeneic graft-versus-host reaction and blasticogenic response of lymphocytes in vitro were also observed in mononuclear cells from cancer patients [75], [76].

Fructus Lycii (Gouqizhi), the ripe fruit of *Lycium barbarum* L. (Solanaeace), is a further Chinese herbal medicine containing polysaccharides with immunostimulating and antitumor activities. It is listed in the Chinese Pharmacopoeia and is used as a general tonic. A number of peptideglycans has been isolated from the fruit [77], [78], [79]. The polysaccharide content in different samples of *L. barbarum* ranges from 5% to 8% [80]. The fruit extract extensively increased the expression of the IL-2 receptor (α- and β-chains) on the membrane of tonsillar mononuclear cells [81]. *Lycium barbarum* polysaccharides increased the weight of spleen and thymus, and reticuloendothelial phagocytosis in normal mice [82]. They enhanced the IL-2 activity from aged mice (16 months) to the same extent as that of adult mice (2 months) [83].

The polysaccharides from *L. barbarum* fruits significantly enhanced the membrane PKC activity of rabbit red blood cells at a concentration of 100 μg/ml [84]. At concentrations of 50–400 μg/ml, the polysaccharide increased both the cellular cAMP and cGMP levels in mouse lymphocytes in a concentration-dependent manner [85]. At daily i.p. doses of 5–10 mg/kg to mice for 7 days, the polysaccharide increased spleen lymphocyte proliferation induced by Con A. The number of plaque-forming cells in the spleen in sheep red cell-immunized mice was increased by the polysaccharide [86]. A single i.p. injection of the fruit polysaccharides at a dose of 10 mg/kg induced proliferation of splenocytes in 12 months old mice, the lymphokine-activated killer cell activities being significantly higher than that of control animals. Combined use of polysaccharides with IL-2 i.p. resulted in a synergistic induction of lymphocyte-activated killer cell activities (LAK) from aged mice in vitro [87]. Furthermore, the polysaccharide was reported to partially or completely reverse the immunosuppressive effect of cyclophosphamide in mice [88].

In a clinical trial, 79 patients with advanced cancer were treated with LAK/IL-2 combining with *L. barbarum* polysaccharides: initial results from 75 evaluable patients indicated that objective regression of cancer was achieved in patients with malignant melanoma, renal cell carcinoma, colorectal carcinoma, lung cancer, and nasopharyngeal carcinoma. The response rate was 41%,
while that of patients treated with LAK/IL-2 alone was 16%. Patients treated with LAK/IL-2 plus polysaccharides showed a significantly longer mean remission period and a more pronounced increase in NK cell and LAK cell activity [89]. The polysaccharide also significantly increased the T lymphocyte blastogenic and phagocytic rate of macrophages in 171 cancer patients after radiotherapy [90].

Experimental studies showed that the polysaccharides enhanced the antineoplastic activity of irradiation and curative treatment in G422 tumor-bearing mice [91]. Furthermore, they exhibited radiosensitizing effects in mice transplanted with Lewis lung cancer [92]. The polysaccharide given to mice bearing S180 tumors significantly decreased tumor weight in a dose-dependent manner and increased the number of splenocytes, and it promoted the activated T cells, NK cell activity and TNFβ levels in tumor bearing mice [93].

Radix Codonopsis Pilosulae (Dangshen), the root of Codonopsis pilosula (Franch.) Nannf., Codonopsis pilosula Nannf. var. modesta (Nannf.), L. T. Shen or Codonopsis tangshen Oliv. (Campanulaceae), listed in the Chinese Pharmacopoeia, is known to contain polysaccharides and to exhibit immunostimulating and antitumor activities. It is used in Traditional Chinese Medicine as a general tonic. Polysaccharides from the root of C. pilosula are composed of glucose, fructose, galactose, arabinose, mannose, rhamnose, xylose, and ribose in different ratios [94].

The extract of the root of C. pilosula was reported to enhance T-lymphocyte activity, but not NK cell activity of human lymphocytes in vitro and to stimulate the production of immunoglobulin by B-cells and of IL-1 by monocytes [95]. The extract of the root of C. pilosula was also reported to stimulate the immunological functions in normal and in cyclophosphamide-suppressed mice [96] as well as in tumor-bearing mice treated with cyclophosphamide [97]. The extract of the root of C. pilosula used as an adjuvant in 76 cancer patients during radiotherapy reduced the immunosuppressive effect of radiation [98].

Ribosome-Inactivating Proteins (RIP)

Ribosome-inactivating proteins (RIP), widespread throughout the plant kingdom, especially from Cucurbitaceae, are a group of proteins able to inactivate eukaryotic protein synthesis by attacking the 28S ribosomal RNA [99]. One of the first isolated, purified and sequenced RIP was trichosanthin from the root of Trichosanthes kirilowii Maxim. (Cucurbitaceae). Radix Trichosanthis (Tianhuafen), the dried root of Trichosanthes kirilowii or Trichosanthes rosthomii Harms is listed in the Chinese Pharmacopoeia and is used clinically to terminate pregnancy. Besides Radix Trichosanthis, also Fructus Trichosanthis (Gualou), the ripe fruit, Pericarpium Trichosanthis (Gualoupi), the pericarp of the ripe fruits; and Semen Trichosanthis (Gualouzi), the ripe seed of T. kirilowii or T. rosthomii, are listed in the Chinese Pharmacopoeia.

Trichosanthin is a relatively simple linear polypeptide composed of 246(7) amino acid residues with a C-terminus of Asn-Asn-Met or Asn-Asn-Met-Ala with a molecular weight of about 27 kDa [100]. X-ray diffraction and Raman spectroscopy of trichosanthin revealed 8 segments of an α-helix with about 85 amino acids, and 13 strands of β-sheet structure with about 70 amino acids, as well as some extended chains. The α-helices are in the center of the molecule and are surrounded by β-sheets [101].

α-Kirilowin, β-kirilowin and trichokin are further RIP from the seed of T. kirilowii. β-Kirilowin possessing a molecular weight of 27.5 kDa did not show cross-reactivity with trichosanthin. Sequence comparison of the first 10 residues of β-kirilowin with trichosanthin and trichokin indicated 60–70% identity [102]. α-Kirilowin was reported to have a molecular weight of 28.8 kDa. The amino acid composition of α-kirilowin grossly resembled β-kirilowin and other RIP. The N-terminal sequence of α-kirilowin was identical to that of β-kirilowin, at least in the first ten residues [103].

Trichosanthin inactivated ribosomes and arrested protein synthesis by removing a specific adenine from 28S rRNA. Experiments on the binding modes of trichosanthin with oligonucleotides GAG, GAGA, and CGAGAG as substrates showed that all the oligonucleotides can dock into the active cleft of trichosanthin without unfavorable contacts [104], [105]. Positions 120–123 of the native trichosanthin molecule may play a critical role in maintaining the inhibition of protein biosynthesis [106], [107]. Fragments corresponding to amino acids 1–72 and 153–246 are supposed to be the antigenic sites [108].

Trichosanthin was found to inhibit the growth of trichoblastic cells. It is therefore used for the treatment of abnormal growth of trichoblastic cells such as hydatiform and malignant moles and choriocarcinomas [109]. Studies on the in vitro cytotoxicity of trichosanthin showed that it selectively damaged choriocarcinoma and melanoma cells whereas hepatoma cells were resistant to the treatment. Cytotoxicity profiles of trichosanthin differed from those of anti-cancer drugs which interfere with DNA metabolism. The N-terminal peptides composed of amino acid residues 1–15 and 16–30 caused increases in concanavalin A (ConA) stimulated incorporation of [H]thymidine into normal spleen cells at a concentration of 5 μg/ml. These peptides also showed growth inhibitory effects against L1210 leukemic cells in vivo [110].

Clinical trials using trichosanthin for the treatment of hydatidiform mole were successful in 44 of 52 patients (85%) including 38 complete remissions (73%) and 6 incomplete remissions (12%) [111]. In vitro studies revealed that trichosanthin induced the generation of reactive oxygen species in human choriocarcinoma cell line (JAR cells). The formation of reactive oxygen species induced by trichosanthin was dependent on the presence of extracellular Ca2+ and involved in the apoptosis of JAR cells [112]. Trichosanthin also induced apoptosis of HeLa cells [113].

The conjugation of trichosanthin to monoclonal antibodies formed an immunotoxin able to inhibit the growth of human melanoma and hepatoma cells in vitro. The cytotoxicity of the conjugate to M21 human melanoma cells was 2000-fold higher than that of a mixture composed of antibody and trichosanthin [114]. The cytotoxicity of the immunotoxin composed of trichosanthin and monoclonal antibody was 500-fold higher in inhibiting the growth
of human hepatoma cells as compared to free trichosanthin [115]. The
in vitro cytotoxicity of the conjugated immunotoxin versus human colon carcinoma (LoVo) cells was approximately 150-fold
higher than that of free trichosanthin or 2000-fold higher than
that of the conjugate of trichosanthin with normal mouse
immunoglobulin IgG. In vivo experiments showed that the
immunotoxin also effectively inhibited human colon carcinoma
xenografts in nude mice and prolonged the life span of tumor-
bearing animals without obvious toxic effects to host mice [116].

Luffins, such as luffin-α [117], [118], luffin-β [119] and luffin-S
[120] are RLPs from the fruit and seed of Luffa cylindrica (L.)
Roem. (Cucurbitaceae). Luffins are basic glycoproteins in nature and
possess a molecular weight of approximately 30,000. They are
reported to exhibit abortifacient, antitumor, ribosome inactivat-
ing and immunomodulatory activities [121]. Luffin-α consists of
248 amino acid residues and possesses a relative molecular
weight of 27,021 Da, excluding the attached sugar chains present
at each Asn residue of positions 28, 33, 77, 84, 206, and 227. Reti-
nervus Luffae Fructus (Signalu), the fibrovascular bundle of the
ripe fruits of L. cylindrica, is listed in the Chinese Pharmacopoeia.
Luffin-α has been observed to inhibit the proliferation and to
induce apoptosis of human melanoma cells in vitro [122], [123].

Further known RLPs from Chinese herbal medicines are e.g. co-
chinchinin and momorcoon S from the seeds of Momordica
cochinchinensis (Lour.) Spreng. (Cucurbitaceae) [124], [125]; cin-
namomin and camphor from the seeds of Cinnamomum
camphora (L.) Sieb. (Laureaceae) [126], [127], [128], [129]; poke-
weed antiviral proteins from the leaves and seeds of Phytolacca
americana L. (Phytolaccaceae) [130], [131]; ricin from the seeds of Ricinus communis L. (Euphorbiaceae). Semen Momordicae
(Mubiezis), the ripe seed of M. cochinchinensis; Semen Ricini (Bi-
mazi), the ripe seed of R. communis; Radix Phytolaccae (Shanglu),
the root of P. americana and P. acinosa are listed in the Chinese
Pharmacopoeia. Pokeweed antiviral proteins [132], [133] and ric-
in [134] are used for the preparation of immunotoxin with
monoclonal antibody. Ricin immunotoxins have been entered in
clinical trials mainly in the treatment of lymphomas [134], [135],
[136], [137], [138], [139], [140].

Conclusion
High molecular compounds from Chinese herbal medicines, in-
cluding ribosome-inactivating proteins and polysaccharides
from both fungi and high plants have been tested for the treat-
mant of malignant diseases. Polysaccharides possessing immu-
nostimulating activities can be used as adjuvants in tumor treat-
ment. The fungi containing such polysaccharides are usually ed-
ible mushrooms or tonics in Traditional Chinese Medicine. Parts
from high plants such as Radix Astragali and Fructus Lycii con-
taining polysaccharides are mainly used as tonic in Traditional
Chinese Medicine. Ribosome-inactivating proteins are a group of
proteins exerting cytotoxic activities via inhibition of protein
synthesis. Some of the ribosome-inactivating proteins have been
used as the cytotoxic part in conjugates with monoclonal antibodies as tumor-targeting drugs. The cytotoxic and antineo-
plastic mechanisms of the high molecular compounds are rather
different from those of the low molecular compounds described
in part I (see footnote 3, p. 193). Obviously, because of genetic
factors that influence enzyme levels accounting for sometimes
striking differences in metabolism and pharmacokinetics of
drugs, results obtained in clinical studies carried out in China or
Japan are not transferable to 100% to the European population.
Since many of the clinical studies referred to in this paper have
been carried out on Asians, the outcome of such studies in
Caucasians or Africans might not be the same.

References
1 Kidd PM. The use of mushroom glucans and proteoglycans in cancer
2 Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysac-
3 Chihara G, Hamuro J, Maeda Y, Arai Y, Fukuoka F. Fractionation and
purification of the polysaccharides with marked antitumor activity,
especially lentican, from Lentinus edodes (Berk.) Sing. (an edible
4 Shida M, Ushioda Y, Nakajima T, Matsuda K. Structure of the alkali-insol-
bale skeletal glucan of Lentinus edodes. J Biochem (Tokyo) 1981; 90:
1093 – 100
5 Wang GL, Lin ZB. The immunomodulatory effect of lentican. Acta
Pharm Sin 1996; 31: 86 – 90
6 Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Ku-
mada K. A multi-institutional prospective study of lentican in ad-
vanced gastric cancer patients with unexpectable and recurrent dis-
 ease: effect on prolongation of survival and improvement of quality of
Successful treatment of hepatic metastasis of gastric cancer with 5-FU
8 Mio H, Terabe K. Clinical effects of postoperative immunother-
rapy with a combination of 5-FU, CDDP and lentican for stage I b
gastric carcinoma and long-term pharmacokinetic studies on CDDP and
5-FU. Gan To Kagaku Ryoho 1997; 24: 337 – 42
9 Taguchi T. Clinical efficacy of lentican on patients with stomach can-
cer: end point results of a four-year follow-up survey. Cancer Detect
10 Takeshita K, Hayashi S, Tani M, Kando F, Saito N, Endo M. Monocyte
function associated with intermittent lentican therapy after resec-
11 Arinaga S, Karimine T, Takamuku K, Nanbara S, Nagamatsu M, Ueo H,
et al. Enhanced production of interleukin 1 and tumor necrosis factor
by peripheral monocytes after lentican administration in patients with
12 Arinaga S, Karimine T, Takamuku K, Nanbara S, Inoue H, Nagamatsu
after lentican administration in patients with gastric carcinoma. Int
J Immunopharmacol 1992; 14: 535 – 9
Clinical study of biological response modifiers as maintenance ther-
apy for hepatocellular carcinoma. Cancer Chemother Pharmacol
1994; 33 Suppl: 145 – 8
14 Chihara G. Preclinical evaluation of lentican in animal models. Adv
15 Li JF, Guo JW, Huang XF. Study on the enhancing effect of poly
porous polysaccharide, mycobacterium polysaccharide and lentican on
lymphocyte-activated killer cell activity in vitro. Chin J Integr Ther
16 Liu F, Ooi VE, Fung MC. Analysis of immunomodulating cytokine
mRNAs in the mouse induced by mushroom polysaccharides. Life
Sci 1999; 64: 1005 – 11
Effects of 5'-DFUR and lentican on cytokines and PnNPase against
18 Murata T, Hatayama I, Kakizaki I, Saitoh K, Sato K, Tsuji S, Lentinan
enhances sensitivity of mouse colon 26 tumor to cis-diaminodi-
chloroplatinum (II) and decreases glutathione transferase expression.
Jpn J Cancer Res 1996; 87: 1171 – 8
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
115 Wang QC, Ying WB, Xie H, Zhang ZC, Yang ZH, Ling LQ. Trichosanthin-monomodal antibody conjugate specifically cytotoxic to human he¬
116 Gao HL, Zhou GY, Lu DY, Zhang WY. Trichosanthin – CEA Mab conjug¬
ate cytotoxic to human colon carcinoma. Chin J Immunol 1992; 8: 300 – 3
118 Chen RS, Leung HW, Dong YC, Wong RN. Modeling of the three-di-
119 Kataoka J, Habuka N, Miyano M, Masuta C, Koivai A. Nucleotide se-
quence of cDNA encoding β-luffin, another ribosome-inactivating protein from Luffa cylindrica. Plant Mol Biol 1993; 19: 887 – 9
121 Ng TB, Chan WY, Yeung HW. Proteins with abortifacient, ribosome in-
activating, immunomodulatory, antitumor and anti-AIDS activities from Cucurbitaceae plants. Gen Pharmacol 1992; 23: 579 – 90
122 Poma A, Marcozzi G, Cesare P, Carmignani M, Spano L. Antiprolifera-
tive effect and apoptotic response in vitro of human melanoma cells to liposomes containing the ribosome-inactivating protein luffin. Bio-
chim Biophys Acta 1997: 192 – 205
123 Poma A, Miranda M, Spano L. Differential response of human melanoma
and Ehrlich ascites cells in vitro to the ribosome-inactivating pro-
124 Huang B, Ng TB, Fong WP, Wan CC, Yeung HW. Isolation of a trypsin inhibi-
tor with deletion of N-terminal pentapeptide from the seeds of Momordica cochinchinensis, the Chinese drug mubiezhi. Int J Biochem Cell
Biol 1999; 31: 707 – 15
127 Xu YZ, Li YJ, Hu HY, Hu R, Wu H, Liu WY. Adenine nucleotide N-glyco-
sidase activity of the A-chain of cinnamomarin characterized by 1H-nu-
128 Ruan JP, Chen WF, Liu WY. Promotion of ATP and S-140 to ribosome inactivation with camphorin, cinnamomarin, and other RNA N-glycosi-
131 Ferens WA, Hovde CJ. Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte prolifer-
132 Schlick J, Dulieu P, Desvoyes B, Adami P, Radom J, Jouvenot M. Cyto-
toxic activity of a recombinant GnlR-PAP fusion toxin on human tu-
mor cell lines. FEBS Lett 2000; 472: 241 – 6
kemic activity of TXU (anti-CD7)-pokeweed antiviral protein immu-
134 Zhong RK, van De Winkel JG, Thepen T, Schultz LD, Ball ED. Cytotoxic-
ity of anti-cd64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in scid mice. J Hematother Stem
Cell Res 2001; 10: 95 – 105
135 van Oosterhout YV, van Ernst JL, Bakker HH, Preijers FW, Schatten-
175 – 86
138 Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, et al. A phase I study of combination therapy with immu-
notoxins IgG-HD37-deglycosylated ricin A chain (dGA) and IgG-RFB4-
Treatment to refractory Hodgkin’s lymphoma patients with an anti-
140 Grossbard ML, Mutani PS, Freedman AS, O’Day S, Gribben JG, Rhuda C, et al. A Phase II study of adjuvant therapy with anti-B4-blocked ri-
2392 – 8